[China BD 2025] Insilico Medicine and Menarini (Stemline) enters a 570 million USD license on a  preclinical small molecule asset

Announced Date: 2025-01-10 (January 10, 2025)

Asset Name: Undisclosed

Licensor: InSilico Medicine (China)

Licensee (Buyer): Stemline Therapeutics, a subsidiary of the Menarini Group（Italy）

.

Asset Modality: Small  Molecule

Asset Target: Undisclosed

Potential Indication: solid tumor cancers

Current Stage: IND-enabling

.

Scope of Authority:

Menarini Group will be granted global rights to develop and commercialize the asset. 

.

Deal Detail:

Upfront payment of  $20 million,

Development, regulatory, and commercial milestone payments, total up to $550 million.

Additional royalties based on net sales in the licensed territories.

.

Link:

Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology – Stemline Therapeutics

.

Note:

Chinese Name of Insilico Medicine  英矽智能